Company Overview of The Multiple Myeloma Research Foundation, Inc
Key Executives for The Multiple Myeloma Research Foundation, Inc
Founder and Executive Chairman
Vice President of Communications
Chief Development and Marketing Officer
Compensation as of Fiscal Year 2014.
The Multiple Myeloma Research Foundation, Inc Key Developments
The Multiple Myeloma Research Foundation and GNS Healthcare Announce Collaboration to Identify Potential New Multiple Myeloma Therapies
Jan 7 15
GNS Healthcare announced a collaboration to speed the discovery of innovative treatments for patients with multiple myeloma. The effort will combine the unprecedented genomic and clinical data from the MMRF's CoMMpass Study with revolutionary GNS machine learning platforms and rapid computer simulations. The work supports the development of computer models of myeloma disease that may uncover novel molecular pathways that can prevent progression of disease and address the unmet treatment needs of patients with multiple myeloma. CoMMpass is a longitudinal study of 1,000 newly diagnosed patients with active multiple myeloma. Its objective is to map each of these patients genomic profiles to clinical outcomes to develop a more complete understanding of patient responses to treatments. GNS will use an in silico process, applying its MAX architecture and patented REFS inference engine and simulation platforms to the CoMMpass data. REFS will identify causal drivers and underlying molecular processes of disease progression. REFS will also discover the most likely targets for therapeutics to treat, and perhaps to predict and prevent, relapses and refractory disease. REFS will also discover predictive diagnostic biomarkers that determine which treatments will work and for which patients. The work promises to support physicians and patients with a broader set of individualized treatment protocols mapped to specific molecular and genomic characteristics. GNS has used REFS successfully to advance the research priorities of numerous nonprofit organizations focused on diseases including Huntington’s disease, multiple sclerosis, childhood asthma, Alzheimer's disease and others. Its work ultimately enables next-generation care management solutions focused on reducing adverse events, slowing disease progression and improving therapeutic effectiveness through precision medicine.
Multiple Myeloma Research Foundation Announces New Initiative to Accelerate Development of Targeted Therapies for Multiple Myeloma with Food and Drug Administration (FDA) and National Cancer Institute
Nov 5 14
The Multiple Myeloma Research Foundation announced an initiative designed to accelerate the evaluation of new investigational therapies for multiple myeloma (MM). The MMRF, in collaboration with the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI), pharmaceutical, biotech and diagnostic industry members, academic center leaders and patients, initiated the formal development of a Master Protocol to allow patients to participate in clinical trials evaluating several investigational therapies at once. Complementing the pursuit of novel drug classes and immunotherapies in MM drug development is the promise of identifying new targeted therapies for patients with specific genetic alterations. The MM Master Protocol would enable several, Phase II clinical trials to take place in parallel within a single study design. Patients would be assigned to an appropriate experimental therapy based on an analysis of their genetic alterations. This novel approach, which has recently been applied in other cancers, allows multiple new therapies to be evaluated more rapidly than with a traditional trial design. Decisions to advance an investigational drug to Phase III testing in a specific genetic subgroup, or to test a different drug in this subgroup, can be expedited -- with the goal of getting new drugs to patients faster than ever before. In addition to discussing protocol design, meeting participants addressed the application of minimal residual disease (MRD) measurements as surrogate endpoints for MM clinical trials. Multiple reports suggest that MRD is a strong predictor of long-term progression free survival (PFS) in multiple myeloma.
The Multiple Myeloma Research Foundation, Inc Presents at The Economist Health Care Forum, Sep-17-2014 11:45 AM
Sep 4 14
The Multiple Myeloma Research Foundation, Inc Presents at The Economist Health Care Forum, Sep-17-2014 11:45 AM. Venue: Seaport Boston Hotel, 1 Seaport Lane, Boston, MA 02210, United States. Speakers: Walter M. Capone, Chief Executive Officer, President and Chief Operating Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|